DA-1726
Sources
registry, as of 2026-04-09Stale
https://clinicaltrials.gov/study/NCT06252220
First in Human Study in Subjects With Obesity, But Otherwise Healthy. Overall status RECRUITING. Phases PHASE1. Lead sponsor NeuroBo Pharmaceuticals Inc.. Enrollment 139. Conditions Obesity. This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
ClinicalTrials.gov NCT06252220 protocol and results modules